Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Table 3

Anticancer immune therapy-related adverse drug reactions from the English literature (year: 1950–2017).

Drug class	Drug	Pharmacology	References	Total	Mortality	SJS	SJS/TEN	TEN
Immunomodulators	Aldesleukin	Recombinant interleukin-2	[81, 82]	2	1	0	0	2
	Ipilimumab	CTLA-4 inhibitors	[83]	1	0	1	0	0
	Nivolumab	PD-1 inhibitors	[84, 85]	2	1	0	0	2
	Pembrolizumab	PD-1 inhibitors	[86, 114, 116]	4	0	4	0	0
	Denileukin	Recombinant interleukin-2 and diphtheria toxin	[87]		1	0	0	1
			Total	9	3	5	0	5